Loading…
Loading…
THCX (The Cannabis ETF) is no longer actively trading.
This usually means the fund has been liquidated, merged into another product, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
The fund will invest at least 80% of its total assets in the component securities of the index. It will also invest, under normal circumstances, at least 80% of its net assets, plus borrowings for investment purposes, in exchange listed common stock (or corresponding American Depositary Receipts ("ADRs") of Cannabis Companies. The index is a proprietary, rules-based index designed to track the performance of a portfolio of Cannabis Companies. The fund is non-diversified.
Is THCX's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Green Thumb Industries is one of the few U.S. cannabis companies that has been consistently profitable. The company grew revenue and earnings in the second quarter.
Canopy Growth's cannabis business is showing signs of a turnaround, with revenue growth, improving margins and a narrower EBITDA loss fueling its rally.
Christina Lake signs non-binding LOI for a proposed $15M acquisition of all its shares, subject to due diligence, debt repayment and definitive agreement
Shares of Tilray Brands (NASDAQ:TLRY) are up 6% to $4.75 Wednesday afternoon, participating in a broad bid for beaten-down speculative names.
EDMONTON, AB, Aug. 19, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce that it has acquired Internode Pharma Limited, a licensed importer and wholesaler, and HAP Pharma Limited, a licensed pharmacy (the "Companies"). "The acquisition of Internode Pharma Limited and HAP Pharma Limited mark a further strategic milestone for Aurora as we continue to purposefully invest in expanding our leadership in the rapidly growing international medical cannabis market.